Prostate morcellation devices: a systematic review and meta-analysis of clinical outcomes and efficiency.

BJU IntJul 8, 2026 (epub)
Clinical ResearchUrology

Stessy Kutchukian, Pietro Scilipoti, Mikael Abi Abdallah et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the efficiency and safety of prostate morcellators used during enucleation for benign prostatic hyperplasia in 5980 patients. The Piranha morcellator showed the highest unadjusted mean morcellation efficiency at 7.80 g/min, while the VersaCut was significantly less efficient by 2.75 g/min. Bladder mucosal injury was the most common complication reported.

Key findings

  • Piranha morcellator had an unadjusted mean efficiency of 7.80 g/min.
  • VersaCut was significantly less efficient by 2.75 g/min compared to Piranha.
  • Bladder mucosal injury was the most frequently reported complication, but rare across devices.
  • VersaCut had a higher risk of complications compared to Piranha with a risk ratio of 3.22.

Why it matters

Understanding the efficiency and safety profiles of different morcellators can guide clinicians in selecting appropriate devices for prostate enucleation, potentially improving patient outcomes and minimizing complications.

Source

PubMed · PMID 42420210

Published in BJU Int. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Urology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.